Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918422 · ClinicalTrials.gov registry record · NA
Controlled Clinical Study to Determine Novel Health Benefits of Cheese Consumption
A NA study of Metabolic Syndrome X, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02918422 is a NA study of Metabolic Syndrome X that has completed, run by Ohio State University. The registered enrollment target is 16 participants, below the 71-participant average among 10 other Metabolic Syndrome X trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02918422, a NA study of Metabolic Syndrome X, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effects of high cheese diets varying in carbohydrate content on markers of disease risk.
Conditions Studied
Interventions
- OTHER Nutritional and Dietary Manipulation
Study Locations (1)
Ohio
- Physical Activity and Education Services - PAES - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918422
The ClinicalTrials.gov registry entry for NCT02918422 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 71-participant average among 10 other Metabolic Syndrome X trials with a reported enrollment target (77% lower). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metabolic Syndrome X appearing as the primary indexed condition, and to 1 intervention - of which Nutritional and Dietary Manipulation is the first listed.
NCT02918422 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02918422 about?
NCT02918422 is a clinical study titled "Controlled Clinical Study to Determine Novel Health Benefits of Cheese Consumption". To determine the effects of high cheese diets varying in carbohydrate content on markers of disease risk.
What is the current status of trial NCT02918422?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2015-09. Estimated completion is 2018-12.
What conditions does trial NCT02918422 study?
This clinical trial studies the following conditions: Metabolic Syndrome X.
What interventions are being tested in trial NCT02918422?
The interventions under investigation include: Nutritional and Dietary Manipulation (OTHER).
Who is sponsoring clinical trial NCT02918422?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02918422 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Syndrome X
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers
COMPLETED · NA
-
Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults
COMPLETED · NA
-
Collaborative Care for Heart Failure Patients With the Metabolic Syndrome
COMPLETED · NA
-
Effects of Resistance and Aerobic Exercise on Cardiovascular Health
COMPLETED · Phase 2
-
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
COMPLETED · Phase 4
-
Diurnal Variation of Plasminogen Activator Inhibitor-1
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.